Pfizer Licenses Starna's Autoimmune Disease Therapies

Pfizer Inc. (NYSE: PFE) today announced that it entered into an exclusive licensing agreement with Starna Therapeutics, a biotechnology company developing RNA medicines designed to enable in vivo therapeutics. Under the agreement, Pfizer obtains exclusive rights outside Greater China to develop, manufacture and commercialize three pre-IND in vivo chimeric antigen receptor T-cell (CAR-T) programs that are focused on treating autoimmune diseases. Pfizer also receives rights to use Starna's proprietary in vivo CAR-T technology in inflammation and immunology, and in oncology, as well as options to exclusively license compounds created under a separate research collaboration and an option to expand the territory to include exclusive rights to develop and commercialize each exclusively licensed compound and product in Greater China.

"In vivo CAR-T is an emerging and promising approach for treating autoimmune diseases, and the patients who might benefit most are those for whom today's options fall short. Pfizer has significant experience in developing and manufacturing RNA-based medicines globally, and Starna's in vivo CAR-T programs and technology give us a powerful way to pursue these approaches."

- Michael Vincent, M.D., Ph.D., Chief Inflammation & Immunology Officer, Pfizer

"Our vision at Starna is to unlock the potential of RNA medicines to transform patient care. We believe our proprietary targeted LNP delivery platform and RNA technology provide a strong foundation for advancing in vivo CAR-T therapies. We are excited to join forces with Pfizer, a global leader in drug development, to bring transformative therapies to patients worldwide."

- Rongkuan Hu, Ph.D., Chief Executive Officer, Starna Therapeutics

Deal Terms and Financial Details

  • Starna will receive an upfront payment of $330 million.
  • Starna is eligible to receive up to $2.3 billion in milestone payments associated with certain development and commercial milestones, plus royalties on net sales of approved products.
  • Pfizer will lead clinical development outside Greater China and plans to manufacture the finished drug product for the initial clinical trials using its facilities in the United States.
  • Pfizer will have sole and exclusive control over commercialization outside of Greater China for all products.
  • Pfizer holds options to expand its territory to include Greater China.

Advancing Promising Science for Patients

Today's agreement broadens Pfizer's Inflammation & Immunology pipeline and enables Pfizer to deploy its extensive scientific expertise in RNA delivery and specialization in immunology research, clinical development and commercialization to a promising, next-generation approach in cell therapy. Starna's innovative technology provides future opportunities to design potentially transformative autoimmune and cancer treatments.

/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.